Khảo sát tình hình sử dụng thuốc và biến cố bất lợi trên bệnh nhân đa u tuỷ xương tại Viện Huyết học - Truyền máu Trung ương=Survey on medicine use and adverse events in patients with multiple myeloma at National Institute of Hematology and Blood Transfusion

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Bích Hà Bùi, Thị Thuý Đỗ, Phương Thảo Lê, Lan Phương Nguyễn, Minh Tuấn Phạm, Thị Thanh Bình Võ, Đức Bình Vũ, Duy Hồng Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.226-237

Bộ sưu tập: Metadata

ID: 478242

Thêm vào giỏ

Khảo sát tình hình sử dụng thuốc điều trị trên bệnh nhân đa u tủy xương và khảo sát biến cố bất lợi trên bệnh nhân đa u tủy xương. Đối tượng và phương pháp: Nghiên cứu hồi cứu mô tả 106 bệnh nhân ≥ 18 tuổi được chẩn đoán xác định mắc đa u tuỷ xương (ĐUTX). Bệnh nhân được điều trị nội trú từ chu kỳ đầu tại Viện Huyết học - Truyền máu Trung ương, có hồ sơ bệnh án ra viện trong khoảng thời gian từ 01/04/2021 đến 31/12/2021. Thu thập thông tin từ phần mềm quản lý bệnh viện và hồ sơ bệnh án tương ứng vào mẫu phiếu thu thập thông tin bệnh nhân. Kết quả: Độ tuổi trung bình của bệnh nhân nghiên cứu là 64,3 ± 9,2 (38 - 85). Đa phần bệnh nhân ĐUTX nhập viện ở giai đoạn 3 tại thời điểm chẩn đoán (56,6%). Phác đồ được sử dụng trên bệnh nhân mới chẩn đoán chủ yếu là VTD (82,1%), tiếp đến là phác đồ VRD (8,5%). Với bệnh nhân có kế hoạch ghép TBG, tỷ lệ phác đồ được sử dụng lần lượt là VTD (62,5%), VRD (25,0%), VTD-PACE (12,5%). Các biến cố bất lợi: Thiếu máu chiếm tỷ lệ 80,9%
sau đó là biến cố tổn thương thần kinh ngoại biên (TKNB) cảm giác (tê bì, ngứa ran, châm chích bàn tay/chân) chiếm tỷ lệ 45,7%
giảm bạch cầu trung tính (BCTT) chiếm tỷ lệ 40,2%
giảm tiểu cầu chiếm 39,7%
tăng ALT chiếm 34,2%. Biến cố nhiễm trùng: Viêm họng 27,6%
viêm phổi 9,5%. Các biến cố bất lợi trên lâm sàng gồm mất ngủ, chán ăn, mệt mỏi, mẩn ngứa da với các tỷ lệ tương ứng là 36,4%
31,7%
30,7% và 25,9%. Kết luận: Đa phần bệnh nhân ĐUTX nhập viện ở giai đoạn 3 tại thời điểm chẩn đoán. Phác đồ được sử dụng trên bệnh nhân mới chẩn đoán chủ yếu là VTD. Các biến cố bất lợi thường gặp: thiếu máu, tổn thương thần kinh ngoại biên (TKNB) cảm giác (tê bì, ngứa ran, châm chích bàn tay/chân)
giảm bạch cầu trung tính (BCTT)
giảm tiểu cầu
tăng ALT.Survey the use of treatment drugs in patients with multiple myeloma and survey adverse events in patients with multiple myeloma. Subjects and methods: Retrospective study describing 106 patients ≥ 18 years old diagnosed with multiple myeloma (MM). Patients were treated as inpatients from the first cycle at the National Institute of Hematology and Blood Transfusion, with medical records discharged from the hospital between April 1, 2021 and December 31, 2021. Collect information from hospital management software and corresponding medical records on the patient information collection form. Results: The average age of the study patients was 64.3 ± 9.2 (38 - 85). Most of the MMM patients were hospitalized in stage 3 at the time of diagnosis (56.6%). The regimen used in newly diagnosed patients was mainly VTD (82.1%), followed by VRD (8.5%). For patients planning to undergo stem cell transplantation, the regimens used were VTD (62.5%), VRD (25.0%), and VTD-PACE (12.5%), respectively. Adverse events: Anemia accounted for 80.9%
followed by peripheral nerve damage (PND) sensory events (numbness, tingling, prickling of hands/feet) at 45.7%
neutropenia (BCTT) at 40.2%
thrombocytopenia at 39.7%
increased ALT at 34.2%. Infectious events: Pharyngitis 27.6%
pneumonia 9.5%. Clinical adverse events included insomnia, anorexia, fatigue, and skin rash at 36.4%, respectively
31.7%
30.7% and 25.9%. Conclusion: Most of the patients with DUTX were hospitalized in stage 3 at the time of diagnosis. The regimen used on newly diagnosed patients was mainly VTD. Common adverse events: anemia, peripheral neuropathy (PND) sensory (numbness, tingling, prickling of hands/feet)
neutropenia (BCTT)
thrombocytopenia
increased ALT.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR